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Virtual meetings, virtual travel podcasts,  and virtual
family reunions — a 21st century shift forced upon us
by  the  coronavirus  disease  2019  (COVID-19)
pandemic — are an urgent leap forward to a new way
of working and socialising.
But the dialogue is now changing in anticipation of
a shift back to the way it was before COVID-19 — to
the era some are calling “Before COVID-19” or BC19.
This  anticipation  is  occurring  because  the
epidemiology  of  the  COVID-19  virus* has  become
more  clearly  understood — given  a  kickstart  by  the
extensive research done by Chinese researchers early in
the pandemic and continuing today; and because there
are  now  an  astounding  number  of  easier  to  use
diagnostic  tests,  vaccines,  and  therapeutics  that  were
only a hope one year ago.
But  will  this  shift  back  to  BC19 benefit  from what
we have learned from living in the virtual world during
the  past  year — that  virtual  meetings  can  have  the
hoped  for  outcomes,  that  travel  podcasts  can  provide
new  thoughts  and  experiences,  and  that  virtual
reunions  can  keep  families  close  together  across  long
distances.  Will  there  be  a  mix  of  virtual  and  real
international travel in BC19, and will this prolong the
glimpse  of  benefits  that  the  decrease  in  international
travel has brought to our environment and to our own
well being (1)? Or will the pandemic have been a glitch
in  our  usual  way  of  life  that  rapidly  disappears — in
fact, there is an omen that this might be true.
Though  it  is  too  early  to  know  how  the  shift  to
BC19 will finally play out, especially as variants of the
COVID-19 virus continue to evolve,  there is  clearly a
sense  of  great  urgency  to  get  back  to  international
travel  (2).  International  travel  is  perceived  to  be  as
important today as it has been since the establishment
of  the  great  trade  routes  in  history  including  the  Silk
Road,  the  trade  route  that  linked  people  and  goods
from  the  Middle  East  and  China  to  the  Western
world.  The  Silk  Road,  and  many  other  networks  of
human  travel  and  trade,  were  often  interrupted  by
pandemics — plague,  cholera,  and  smallpox — yet
they came back and continued to evolve and increase as
new means of public conveyance were developed.
Yellow  fever  is  a  good  recent  example  of  how  an
infectious  disease  slowed  and  disrupted  international
travel and trade, such as in the early 20th century when
yellow  fever  outbreaks  disrupted  the  construction  of
the  Panama  Canal.  They  had  become  a  concern  for
international  travel  within  the  Americas  in  the  late
19th  century  when  major  urban  outbreaks  occurred
where  yellow  fever  had  not  been  previously  recorded
(3). Innovation prevailed, however, and in the 1930s a
yellow  fever  vaccine  was  developed  that  prevented  its
infection and transmission and all was changed (4).
Along the road to BC19, late last year Hong Kong,
China and Singapore conceived a way of ensuring safer
international  travel  between  each  of  their  massive
urbanised  areas — what  they  called  a “travel  bubble.”
But  by  the  end  of  December  the  travel  bubble  had
burst  (5).  One  of  the  perceptions  for  creating  the
bubble appeared to be that equal risk of infection and
equal  detection  and  response  capacity,  along  with
strategic  testing  for  COVID-19  virus,  could  lead  to
decreased  risk  of  infection  during  travel  and  upon
landing.  An  increase  in  reported  infections  in  one  of
these  two  urban  areas,  however,  caused  a  perceived
imbalance  in  the  risk  and plans  were  abandoned.  The
mantra  of  equal  risk  and  equal  response  capacity  and
safe travel was shown to be difficult to implement but
is  a  goal  still  being  sought.  And  as  a  follow  up,  the
World  Health  Organization  is  developing  a  risk
assessment  framework  to  help  countries  estimate  and
compare their travel risks.
And  today  there  are  vaccines  as  well.  Just  as  in  the
1930s  when the  newly  developed yellow fever  vaccine
led to prevention of infection and transmission and to
safer  international  travel  in  the  Americas,  COVID-19
vaccines are giving the same hope — that international
travel  will  again  become  safe,  returning  the  world  of
international travel to its BC19 level.
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In  fact  there  is  talk  of “vaccine  or  immunity
passports” and  of  international  vaccination  cards  as  a
means of ensuring safe international travel, minimising
both  the  risk  of  transmission  in  airports  and
airplanes (6).
But while vaccines provide almost complete personal
protection against serious illness and death — the end
point in the studies conducted for licensing — there is
still  not  evidence as  to  whether  these  vaccines  prevent
infection or whether they modify infection once it has
occurred.  And  there  is  not  yet  evidence  to  help
understand  how  long  the  protective  effect  of  these
vaccines will last, and whether new variants of the virus
will  impact  on  protection  though  evidence  is
accumulating (7).
These answers will rapidly become available as more
and more  persons  are  vaccinated  and post-vaccination
surveillance and research continues. For now however,
patience  is  the  byword.  We  know  for  example  that
persons  vaccinated  against  polio  are  protected  from
infection, but they can still carry wild poliovirus in the
gut and transmit to others. And we also know that for
some  bacterial  vaccines — the  polysaccharide
meningitis  vaccine  for  example — nasal  carriage  of
meningitis  bacteria  was  possible  and  only  rectified  by
innovation  of  a  conjugate  vaccine  that  eliminates  this
carriage.
Though  there  is  some  evidence  that  some  of  the
COVID-19  vaccines  decrease  nasal  carriage  of
COVID-19 virus from small subsets of persons studies
in  clinical  trials,  more  information  is  required  along
with that about duration of the protective response.
So returning to BC19 for international travel is still
a  cautious  journey — there  is  a  need  for  continued
understanding and innovation using the tools we have
today,  and  the  will  that  we  can  and  must  return  in  a
more  environmentally  friendly  way.  But  there  is  one
caveat — and that relates to an unsubstantiated report
of  neighbour  who  recently  returned  on  an
international  flight.  His  certification of  a  negative  test
for  COVID-19  came  from  a  template  in  the  virtual
world  of  the  internet — not  from  a  medically
authorised laboratory.
The road is long for the return to international travel
BC19 and presents many challenges along the way. 
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